Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Cystic Fibrosis · Rheumatoid Arthritis · LKFT

Lakefront Biotherapeutics NV

Lakefront Biotherapeutics NV clinical programs — 99 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Yalelaan 60, 5th floor, Utrecht 3584 CM, NL HQ
2016 Founded
9 Employees
Public company Type
LKFT · NYSE Ticker
Company details
Status
Public
HQ
Yalelaan 60, 5th floor, Utrecht 3584 CM, NL
Founded
2016
Employees
9
Programs
99
Drugs
26
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Lakefront Biotherapeutics NV projects

99 ClinicalTrials.gov programs sponsored by Lakefront Biotherapeutics NV.

Lakefront Biotherapeutics NV has 99 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

99 programs

Clinical programs

Page 2 of 3

  1. GLPG0555

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    2 trials

  2. GLPG0555 solid dispersion

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  3. GLPG0634

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    3 trials

  4. GLPG0634

    Lakefront Biotherapeutics NV

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  5. GLPG0634 100mg capsule once a day for 10 days

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  6. GLPG0634 50 mg

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  7. GLPG0778

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    2 trials

  8. GLPG0974

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    2 trials

  9. GLPG1205

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    2 trials

  10. GLPG1205 50mg q.d.

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  11. GLPG1205 film-coated tablets

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  12. GLPG1205 single ascending doses, oral suspension

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  13. GLPG1690

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    2 trials

  14. GLPG1690 film-coated tablets

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  15. GLPG1690 single ascending doses

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  16. GLPG1837 500 mg

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  17. GLPG1837 single ascending doses

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  18. GLPG1972

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  19. GLPG1972 - A

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  20. GLPG1972 600 mg oral solution fasted

    Lakefront Biotherapeutics NV

    Osteoarthritis

    phase 1 small molecule completed

    1 trial

  21. GLPG1972 cohort 1

    Lakefront Biotherapeutics NV

    Osteoarthritis

    phase 1 small molecule completed

    1 trial

  22. GLPG1972 film-coated tablets

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  23. GLPG1972 single ascending doses

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  24. GLPG2222 single dose

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  25. GLPG2451 dose regimen A

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 1 small molecule completed

    1 trial

  26. GLPG2451 multiple dose

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  27. GLPG2451 single dose

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  28. GLPG2737 single dose

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 1 small molecule completed

    1 trial

  29. GLPG2737 single dose

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  30. GLPG3067 single dose

    Lakefront Biotherapeutics NV

    Cystic Fibrosis

    phase 1 small molecule completed

    1 trial

  31. GLPG3067 single dose

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  32. GLPG3121

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  33. GLPG3121 SAD

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  34. GLPG3312 IR

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  35. GLPG3667

    Lakefront Biotherapeutics NV

    Plaque Psoriasis

    phase 1 small molecule completed

    1 trial

  36. GLPG3667

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    3 trials

  37. GLPG3667 capsule

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  38. GLPG3667 oral suspension

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  39. GLPG3970 film-coated tablet

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  40. GLPG3970 film-coated tablet

    Lakefront Biotherapeutics NV

    Systemic Lupus Erythematosus

    phase 1 small molecule terminated

    1 trial

  41. GLPG3970 oral solution

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    2 trials

  42. GLPG4059 oral suspension

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule terminated

    1 trial

  43. GLPG4399 oral suspension

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  44. GLPG4716

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  45. MOR106

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule terminated

    1 trial

  46. MOR106 single ascending doses, intravenous

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  47. Pirfenidone

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  48. Sulfasalazine

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Lakefront Biotherapeutics NV have?

99 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.